|Classification and external resources|
|Specialty||Allergy and immunology|
Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. It typically causes a number of symptoms including an itchy rash, throat swelling, and low blood pressure. Common causes include insect bites and stings, foods, and medications. On a mechanistic level, anaphylaxis is caused by the release of mediators from certain types of white blood cells triggered by either immunologic or non-immunologic mechanisms. Clinicians diagnose the condition on the basis of the presenting symptoms and signs. The primary treatment is injection of epinephrine, the administration of intravenous fluids, and positioning the person flat, with other measures being complementary. Worldwide, 0.05–2% of the population is estimated to experience anaphylaxis at some point in life, and rates appear to be increasing. The term comes from the Ancient Greek: ἀνά ana "against", and the Ancient Greek: φύλαξις phylaxis "protection".
Signs and symptoms 1
- Skin 1.1
- Respiratory 1.2
- Cardiovascular 1.3
- Other 1.4
- Food 2.1
- Medication 2.2
- Venom 2.3
- Risk factors 2.4
- Immunologic 3.1
- Non-immunologic 3.2
- Classification 4.1
- Allergy testing 4.2
- Differential diagnosis 4.3
- Post-mortem findings 4.4
- Prevention 5
- Epinephrine 6.1
- Adjuncts 6.2
- Preparedness 6.3
- Prognosis 7
- Epidemiology 8
- History 9
- Research 10
- References 11
- External links 12
Signs and symptoms
Anaphylaxis typically presents many different symptoms over minutes or hours with an average onset of 5 to 30 minutes if exposure is intravenous and 2 hours if from eating food. The most common areas affected include: skin (80–90%), respiratory (70%), gastrointestinal (30–45%), heart and vasculature (10–45%), and central nervous system (10–15%) with usually two or more being involved.
Symptoms typically include generalized hives, itchiness, flushing, or swelling (angioedema) of the afflicted tissues. Those with angioedema may describe a burning sensation of the skin rather than itchiness. Swelling of the tongue or throat occurs in up to about 20% of cases. Other features may include a runny nose and swelling of the conjunctiva. The skin may also be blue tinged because of lack of oxygen.
Respiratory symptoms and signs that may be present include shortness of breath, wheezes, or stridor. The wheezing is typically caused by spasms of the bronchial muscles while stridor is related to upper airway obstruction secondary to swelling. Hoarseness, pain with swallowing, or a cough may also occur.
Coronary artery spasm may occur with subsequent myocardial infarction, dysrhythmia, or cardiac arrest. Those with underlying coronary disease are at greater risk of cardiac effects from anaphylaxis. The coronary spasm is related to the presence of histamine-releasing cells in the heart. While a fast heart rate caused by low blood pressure is more common, a Bezold–Jarisch reflex has been described in 10% of cases where a slow heart rate is associated with low blood pressure. A drop in blood pressure or shock (either distributive or cardiogenic) may cause the feeling of lightheadedness or loss of consciousness. Rarely very low blood pressure may be the only sign of anaphylaxis.
Gastrointestinal symptoms may include crampy abdominal pain, diarrhea, and vomiting. There may be confusion, a loss of bladder control or pelvic pain similar to that of uterine cramps. Dilation of blood vessels around the brain may cause headaches. A feeling of anxiety or of "impending doom" has also been described.
Anaphylaxis can occur in response to almost any foreign substance. Common triggers include venom from insect bites or stings, foods, and medication. Foods are the most common trigger in children and young adults while medications and insect bites and stings are more common in older adults. Less common causes include: physical factors, biological agents such as semen, latex, hormonal changes, food additives such as monosodium glutamate and food colors, and topical medications. Physical factors such as exercise (known as exercise-induced anaphylaxis) or temperature (either hot or cold) may also act as triggers through their direct effects on mast cells. Events caused by exercise are frequently associated with the ingestion of certain foods. During anesthesia, neuromuscular blocking agents, antibiotics, and latex are the most common causes. The cause remains unknown in 32–50% of cases, referred to as "idiopathic anaphylaxis." Six vaccines (MMR, varicella, influenza, hepatitis B, tetanus, meningococcal) are recognized as a cause for anaphylaxis, and HPV may cause anaphylaxis as well.
Many foods can trigger anaphylaxis; this may occur upon the first known ingestion. Common triggering foods vary around the world. In Western cultures, ingestion of or exposure to peanuts, wheat, nuts, certain types of seafood like shellfish, milk, and eggs are the most prevalent causes. Sesame is common in the Middle East, while rice and chickpeas are frequently encountered as sources of anaphylaxis in Asia. Severe cases are usually caused by ingesting the allergen, but some people experience a severe reaction upon contact. Children can outgrow their allergies. By age 16, 80% of children with anaphylaxis to milk or eggs and 20% who experience isolated anaphylaxis to peanuts can tolerate these foods.
Any medication may potentially trigger anaphylaxis. The most common are β-lactam antibiotics (such as penicillin) followed by aspirin and NSAIDs. Other antibiotics are implicated less frequently, and the reactions to NSAIDs are agent specific meaning that those who are allergic to one NSAID can typically tolerate a different one. Other relatively common causes include chemotherapy, vaccines, protamine and herbal preparations. Some medications (vancomycin, morphine, x-ray contrast among others) cause anaphylaxis by directly triggering mast cell degranulation.
The frequency of a reaction to an agent partly depends on the frequency of its use and partly on its intrinsic properties. Anaphylaxis to penicillin or cephalosporins occurs only after it binds to proteins inside the body with some agents binding more easily than others. Anaphylaxis to penicillin occurs once in every 2,000 to 10,000 courses of treatment, with death occurring in fewer than one in every 50,000 courses of treatment. Anaphylaxis to aspirin and NSAIDs occurs in about one in every 50,000 persons. If someone has a reaction to penicillins, his or her risk of a reaction to cephalosporins is greater but still less than one in 1,000. The old radiocontrast agents caused reactions in 1% of cases, while the newer lower osmolar agents cause reactions in 0.04% of cases.
Venom from stinging or biting insects such as Hymenoptera (ants, bees and wasps) or Triatominae (kissing bugs) may cause anaphylaxis in susceptible people. Previous systemic reactions, which are anything more than a local reaction around the site of the sting, are a risk factor for future anaphylaxis; however, half of fatalities have had no previous systemic reaction.
People with atopic diseases such as asthma, eczema, or allergic rhinitis are at high risk of anaphylaxis from food, latex, and radiocontrast but not from injectable medications or stings. One study in children found that 60% had a history of previous atopic diseases, and of children who die from anaphylaxis, more than 90% have asthma. Those with mastocytosis or of a higher socioeconomic status are at increased risk. The longer the time since the last exposure to the agent in question, the lower the risk.
Anaphylaxis is a severe allergic reaction of rapid onset affecting many body systems. It is due to the release of inflammatory mediators and cytokines from mast cells and basophils, typically due to an immunologic reaction but sometimes non-immunologic mechanism.
In the immunologic mechanism, immunoglobulin E (IgE) binds to the antigen (the foreign material that provokes the allergic reaction). Antigen-bound IgE then activates FcεRI receptors on mast cells and basophils. This leads to the release of inflammatory mediators such as histamine. These mediators subsequently increase the contraction of bronchial smooth muscles, trigger vasodilation, increase the leakage of fluid from blood vessels, and cause heart muscle depression. There is also an immunologic mechanism that does not rely on IgE, but it is not known if this occurs in humans.
Non-immunologic mechanisms involve substances that directly cause the degranulation of mast cells and basophils. These include agents such as contrast medium, opioids, temperature (hot or cold), and vibration. Sulfites may cause reactions by both immunologic and non-immunologic mechanisms.
Anaphylaxis is diagnosed on the basis of a person's signs and symptoms. When any one of the following three occurs within minutes or hours of exposure to an allergen there is a high likelihood of anaphylaxis:
- Involvement of the skin or mucosal tissue plus either respiratory difficulty or a low blood pressure causing symptoms
- Two or more of the following symptoms after a likely contact with an allergen:
- Low blood pressure after exposure to a known allergen
Skin involvement may include: hives, itchiness or a swollen tongue among others. Respiratory difficulties may include: shortness of breath, stridor, or low oxygen levels among others. Low blood pressure is defined as a greater than 30% decrease from a person's usual blood pressure. In adults a systolic blood pressure of less than 90 mmHg is often used.
During an attack, blood tests for tryptase or histamine (released from mast cells) might be useful in diagnosing anaphylaxis due to insect stings or medications. However these tests are of limited use if the cause is food or if the person has a normal blood pressure, and they are not specific for the diagnosis.
There are three main classifications of anaphylaxis. Anaphylactic shock is associated with systemic
- Anaphylaxis at DMOZ
- National Institute for Health and Clinical Excellence. Clinical guideline 134: Anaphylaxis: assessment to confirm an anaphylactic episode and the decision to refer after emergency treatment for a suspected anaphylactic episode. London, 2011. and Anaphylaxis pathway
- Sampson HA, Muñoz-Furlong A, Campbell RL; et al. (February 2006). "Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium". The Journal of Allergy and Clinical Immunology 117 (2): 391–7.
- Tintinalli, Judith E. (2010). Emergency Medicine: A Comprehensive Study Guide (Emergency Medicine (Tintinalli)). New York: McGraw-Hill Companies. pp. 177–182.
- Simons, FE; World Allergy, Organization (May 2010). "World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings" (PDF). Annals of Allergy, Asthma & Immunology 104 (5): 405–12.
- Oswalt ML, Kemp SF (May 2007). "Anaphylaxis: office management and prevention". Immunol Allergy Clin North Am 27 (2): 177–91, vi.
- Simons FE (October 2009). "Anaphylaxis: Recent advances in assessment and treatment" (PDF). The Journal of Allergy and Clinical Immunology 124 (4): 625–36; quiz 637–8.
- Marx, John (2010). Rosen's emergency medicine: concepts and clinical practice 7th edition. Philadelphia, PA: Mosby/Elsevier. p. 15111528.
- Limsuwan, T; Demoly, P (July 2010). "Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock)" (PDF). The Medical Clinics of North America 94 (4): 691–710, x.
- Brown, SG; Mullins, RJ, Gold, MS (Sep 4, 2006). "Anaphylaxis: diagnosis and management". The Medical Journal of Australia 185 (5): 283–9.
- Triggiani, M; Patella, V; Staiano, RI; Granata, F; Marone, G (September 2008). "Allergy and the cardiovascular system". Clinical and Experimental Immunology. 153 Suppl 1 (s1): 7–11.
- Lee, JK; Vadas, P (July 2011). "Anaphylaxis: mechanisms and management". Clinical and Experimental Allergy 41 (7): 923–38.
- Boden, SR; Wesley Burks, A (July 2011). "Anaphylaxis: a history with emphasis on food allergy". Immunological Reviews 242 (1): 247–57.
- Worm, M (2010). "Epidemiology of anaphylaxis". Chemical Immunology and Allergy 95: 12–21.
- editors, Marianne Gausche-Hill, Susan Fuchs, Loren Yamamoto, (2007). The pediatric emergency medicine resource (Rev. 4. ed.). Sudbury, Mass.: Jones & Bartlett. p. 69.
- Dewachter, P; Mouton-Faivre, C; Emala, CW (November 2009). "Anaphylaxis and anesthesia: controversies and new insights". Anesthesiology 111 (5): 1141–50.
- editor, Mariana C. Castells, (2010). Anaphylaxis and hypersensitivity reactions. New York: Humana Press. p. 223.
- "Adverse Effects of Vaccines: Evidence and Causality" (PDF). U.S. Institute of Medicine. 2011. Retrieved 2014-01-16.
- Volcheck, Gerald W. (2009). Clinical allergy : diagnosis and management. Totowa, N.J.: Humana Press. p. 442.
- Drain, KL; Volcheck, GW (2001). "Preventing and managing drug-induced anaphylaxis". Drug Safety 24 (11): 843–53.
- Klotz, JH; Dorn, PL, Logan, JL, Stevens, L, Pinnas, JL, Schmidt, JO, Klotz, SA (Jun 15, 2010). ""Kissing bugs": potential disease vectors and cause of anaphylaxis". Clinical Infectious Diseases 50 (12): 1629–34.
- Brown, Simon G. A.; Wu, Qi-Xuan; Kelsall, G. Robert H.; Heddle, Robert J. & Baldo, Brian A. (2001). "Fatal anaphylaxis following jack jumper ant sting in southern Tasmania". Medical Journal of Australia 175 (11): 644–647.
- Bilò, MB (July 2011). "Anaphylaxis caused by Hymenoptera stings: from epidemiology to treatment". Allergy. 66 Suppl 95: 35–7.
- Cox, L; Larenas-Linnemann, D; Lockey, RF; Passalacqua, G (March 2010). "Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System". The Journal of Allergy and Clinical Immunology 125 (3): 569–74, 574.e1–574.e7.
- Bilò, BM; Bonifazi, F (August 2008). "Epidemiology of insect-venom anaphylaxis". Current Opinion in Allergy and Clinical Immunology 8 (4): 330–7.
- Khan, BQ; Kemp, SF (August 2011). "Pathophysiology of anaphylaxis". Current Opinion in Allergy and Clinical Immunology 11 (4): 319–25.
- Lewis, Julius M. Cruse, Robert E. (2010). Atlas of immunology (3rd ed.). Boca Raton, FL: CRC Press/Taylor & Francis. p. 411.
- Lieberman P (September 2005). "Biphasic anaphylactic reactions". Ann. Allergy Asthma Immunol. 95 (3): 217–26; quiz 226, 258.
- Ring, J; Behrendt, H, de Weck, A (2010). "History and classification of anaphylaxis" (PDF). Chemical Immunology and Allergy. Chemical Immunology and Allergy 95: 1–11.
- Anaphylaxis at eMedicine
- Da Broi, U; Moreschi, C (Jan 30, 2011). "Post-mortem diagnosis of anaphylaxis: A difficult task in forensic medicine". Forensic Science International 204 (1–3): 1–5.
- "Emergency treatment of anaphylactic reactions – Guidelines for healthcare providers" (PDF). Resuscitation Council (UK). January 2008. Retrieved 2008-04-22.
- Simons, KJ; Simons, FE (August 2010). "Epinephrine and its use in anaphylaxis: current issues". Current Opinion in Allergy and Clinical Immunology 10 (4): 354–61.
- Tang, AW (Oct 1, 2003). "A practical guide to anaphylaxis.". American Family Physician 68 (7): 1325–32.
- Mueller, UR (August 2007). "Cardiovascular disease and anaphylaxis". Current Opinion in Allergy and Clinical Immunology 7 (4): 337–41.
- Sicherer, SH; Simons, FE, Section on Allergy and Immunology, American Academy of, Pediatrics; Section On Allergy Immunology (March 2007). "Self-injectable epinephrine for first-aid management of anaphylaxis". Pediatrics 119 (3): 638–46.
- Sheikh A, Ten Broek V, Brown SG, Simons FE (August 2007). "H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review". Allergy 62 (8): 830–7.
- Martelli, A; Ghiglioni, D; Sarratud, T; Calcinai, E; Veehof, S; Terracciano, L; Fiocchi, A (August 2008). "Anaphylaxis in the emergency department: a paediatric perspective". Current Opinion in Allergy and Clinical Immunology 8 (4): 321–9.
- Harris, edited by Jeffrey; Weisman, Michael S. (2007). Head and neck manifestations of systemic disease. London: Informa Healthcare. p. 325.
- Leslie C. Grammer (2012). Patterson's Allergic Diseases (7 ed.).
- Koplin, JJ; Martin, PE, Allen, KJ (October 2011). "An update on epidemiology of anaphylaxis in children and adults". Current Opinion in Allergy and Clinical Immunology 11 (5): 492–6.
- Demain, JG; Minaei, AA, Tracy, JM (August 2010). "Anaphylaxis and insect allergy". Current Opinion in Allergy and Clinical Immunology 10 (4): 318–22.
- "anaphylaxis". merriam-webster.com. Retrieved 2009-11-21.
- Vichyanond, P (September 2011). "Omalizumab in allergic diseases, a recent review". Asian Pacific Journal of Allergy and Immunology 29 (3): 209–19.
There are ongoing efforts to develop sublingual epinephrine to treat anaphylaxis. Subcutaneous injection of the anti-IgE antibody omalizumab is being studied as a method of preventing recurrence, but it is not yet recommended.
The term aphylaxis was coined by Charles Richet in 1902 and later changed to anaphylaxis due to its nicer quality of speech. In his experiments, Richet injected a dog with sea anemone (Actinia) toxin in an attempt to protect it. Although the dog had previously tolerated the toxin, on re-exposure with the same dose three weeks later it developed fatal anaphylaxis. Thus instead of inducing tolerance (prophylaxis), when lethal responses resulted from previously tolerated doses, he coined the word ana (without) phylaxis (protection). He was subsequently awarded the Nobel Prize in Physiology or Medicine for his work on anaphylaxis in 1913. The phenomenon itself however has been described since ancient times. The term comes from the Greek words ἀνά, ana, "against", and φύλαξις, phylaxis, "protection".
Currently, anaphylaxis leads to 500–1,000 deaths per year (2.4 per million) in the United States, 20 deaths per year in the United Kingdom (0.33 per million), and 15 deaths per year in Australia (0.64 per million). Mortality rates have decreased between the 1970s and 2000s. In Australia, death from food-induced anaphylaxis occur primarily in women while deaths due to insect bites primarily occur in males. Death from anaphylaxis is most commonly triggered by medications.
The number of people who get anaphylaxis is 4–5 per 100,000 persons per year, with a lifetime risk of 0.05–2%. Rates appear to be increasing: with the numbers in the 1980s being approximately 20 per 100,000 per year, while in the 1990s it was 50 per 100,000 per year. The increase appears to be primarily for food-induced anaphylaxis. The risk is greatest in young people and females.
In those in whom the cause is known and prompt treatment is available, the prognosis is good. Even if the cause is unknown, if appropriate preventative medication is available, the prognosis is generally good. If death occurs, it is usually due to either respiratory (typically asphyxia) or cardiovascular causes (shock), with 0.7–20% of cases causing death. There have been cases of death occurring within minutes. Outcomes in those with exercise-induced anaphylaxis are typically good, with fewer and less severe episodes as people get older.
People prone to anaphylaxis are advised to have an "allergy action plan." Parents are advised to inform schools of their children's allergies and what to do in case of an anaphylactic emergency. The action plan usually includes use of epinephrine autoinjectors, the recommendation to wear a medical alert bracelet, and counseling on avoidance of triggers. Immunotherapy is available for certain triggers to prevent future episodes of anaphylaxis. A multi-year course of subcutaneous desensitization has been found effective against stinging insects, while oral desensitization is effective for many foods.
Antihistamines (both H1 and H2), while commonly used and assumed effective based on theoretical reasoning, are poorly supported by evidence. A 2007 Cochrane review did not find any good-quality studies upon which to base recommendations and they are not believed to have an effect on airway edema or spasm. Corticosteroids are unlikely to make a difference in the current episode of anaphylaxis, but may be used in the hope of decreasing the risk of biphasic anaphylaxis. Their prophylactic effectiveness in these situations is uncertain. Nebulized salbutamol may be effective for bronchospasm that does not resolve with epinephrine. Methylene blue has been used in those not responsive to other measures due to its presumed effect of relaxing smooth muscle.
If necessary, it can also be given intravenously using a dilute epinephrine solution. Intravenous epinephrine however has been associated both with dysrhythmia and myocardial infarction. Epinephrine autoinjectors used for self-administration typically come in two doses, one for adults or children who weigh more than 25 kg and one for children who weigh 10 to 25 kg.
People on β-blockers may be resistant to the effects of epinephrine. In this situation if epinephrine is not effective intravenous glucagon can be administered which has a mechanism of action independent of β-receptors.
Epinephrine (adrenaline) is the primary treatment for anaphylaxis with no absolute contraindication to its use. It is recommended that an epinephrine solution be given intramuscularly into the mid anterolateral thigh as soon as the diagnosis is suspected. The injection may be repeated every 5 to 15 minutes if there is insufficient response. A second dose is needed in 16-35% of episodes with more than two doses rarely required. The intramuscular route is preferred over subcutaneous administration because the latter may have delayed absorption. Minor adverse effects from epinephrine include tremors, anxiety, headaches, and palpitations.
Anaphylaxis is a medical emergency that may require resuscitation measures such as airway management, supplemental oxygen, large volumes of intravenous fluids, and close monitoring. Administration of epinephrine is the treatment of choice with antihistamines and steroids (for example, dexamethasone) often used as adjuncts. A period of in-hospital observation for between 2 and 24 hours is recommended for people once they have returned to normal due to concerns of biphasic anaphylaxis.
Avoidance of the trigger of anaphylaxis is recommended. In cases where this may not be possible, desensitization may be an option. Immunotherapy with Hymenoptera venoms is effective at desensitizing 80–90% of adults and 98% of children against allergies to bees, wasps, hornets, yellowjackets, and fire ants. Oral immunotherapy may be effective at desensitizing some people to certain food including milk, eggs, nuts and peanuts; however, adverse effects are common. Desensitization is also possible for many medications, however it is advised that most people simply avoid the agent in question. In those who react to latex it may be important to avoid cross-reactive foods such as avocados, bananas, and potatoes among others.
In a person who died from anaphylaxis, autopsy may show an "empty heart" attributed to reduced venous return from vasodilation and redistribution of intravascular volume from the central to the peripheral compartment. Other signs are laryngeal edema, eosinophilia in lungs, heart and tissues, and evidence of myocardial hypoperfusion. Laboratory findings could detect increased levels of serum tryptase, increase in total and specific IgE serum levels.
It can sometimes be difficult to distinguish anaphylaxis from asthma, syncope, and panic attacks. Asthma however typically does not entail itching or gastrointestinal symptoms, syncope presents with pallor rather than a rash, and a panic attack may have flushing but does not have hives. Other conditions that may present similarly include: scrombroidosis and anisakiasis.
Skin testing is available to confirm penicillin allergies, but is not available for other medications. Non-immune forms of anaphylaxis can only be determined by history or exposure to the allergen in question, and not by skin or blood testing.
Allergy testing may help in determining the trigger. Skin allergy testing (such as patch testing) is available for certain foods and venoms. Blood testing for specific IgE can be useful to confirm milk, egg, peanut, tree nut and fish allergies.
 with some recommending that the old terminology no longer be used.